Association between polymorphisms in phospholipase A2 genes and the plasma triglyceride response to an n-3 PUFA supplementation: A clinical trial

Lipids in Health and Disease

Volumn 14, Issue 1, 2015, Pages

  Tremblay, Bénédicte L ^a   Cormier, Hubert ^a   Rudkowska, Iwona ^b   Lemieux, Simone ^a   Couture, Patrick ^a,b   Vohl, Marie Claude ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b University Laval   (Canada)

Author keywords

Gene diet interactions; Nutrigenetics; Omega 3 fatty acids; Phospholipase; Plasma lipid levels

Indexed keywords

APOLIPOPROTEIN B100; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 FATTY ACID; PHOSPHOLIPASE A2; PHOSPHOLIPASE A2 GROUP IIA; PHOSPHOLIPASE A2 GROUP IIC; PHOSPHOLIPASE A2 GROUP IID; PHOSPHOLIPASE A2 GROUP IIF; PHOSPHOLIPASE A2 GROUP IVA; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN; 1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; PHOSPHOLIPASE A2 GROUP II; PHOSPHOLIPASE A2 GROUP VI; PLA2G2A PROTEIN, HUMAN; PLA2G2C PROTEIN, HUMAN; PLA2G2D PROTEIN, HUMAN; PLA2G6 PROTEIN, HUMAN; PLA2G7 PROTEIN, HUMAN;

ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; BODY MASS; CALORIC INTAKE; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; LIPID BLOOD LEVEL; LIPID COMPOSITION; MAJOR CLINICAL STUDY; MALE; OBESITY; PERIPHERAL BLOOD MONONUCLEAR CELL; SINGLE NUCLEOTIDE POLYMORPHISM; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; CLINICAL TRIAL; DIETARY SUPPLEMENT; GENETIC ASSOCIATION STUDY; GENETICS;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADULT; DIETARY SUPPLEMENTS; FATTY ACIDS, OMEGA-3; FEMALE; GENETIC ASSOCIATION STUDIES; GROUP II PHOSPHOLIPASES A2; GROUP VI PHOSPHOLIPASES A2; HUMANS; MALE; PHOSPHOLIPASES A2; POLYMORPHISM, SINGLE NUCLEOTIDE; TRIGLYCERIDES;

EID: 84924019213     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/s12944-015-0009-2     Document Type: Article

References (56)

1. World Health Organization. Global Status Report on Non communicable Diseases. Geneva: WHO Library Cataloguing-in-Publication Data; 2011.
2. Cullen P. Evidence that triglycerides are an independent coronary heart disease risk factor. Am J Cardiol. 2000;86:943-9.
3. Wang C, Harris WS, Chung M, Lichtenstein AH, Balk EM, Kupelnick B, et al. n-3 Fatty acids from fish or fish-oil supplements, but not alpha-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: a systematic review. Am J Clin Nutr. 2006;84:5-17.
4. Harris WS. n-3 fatty acids and serum lipoproteins: human studies. Am J Clin Nutr. 1997;65:16455-54.
5. Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Arterioscler Thromb Vasc Biol. 2003;23:e20-e30.
6. Kris-Etherton PM, Innis S, Ammerican DA, Dietitians of Canada. Position of the American dietetic association and dietitians of Canada: dietary fatty acids. J Am Diet Assoc. 2007;107:1599-611.
7. McGuire S. U.S. Department of Agriculture and U.S. Department of Health and Human Services, Dietary Guidelines for Americans, 2010. 7th Edition, Washington, DC: U.S. Government Printing Office, January 2011. Adv Nutr. 2011;2:293-4.
8. National Health and Medical Research Council. Nutrient Reference Values for Australia and New Zealand Including Recommended Dietary Intakes. Edited by NHMRC. 2005. Canberra.
9. Madden J, Williams CM, Calder PC, Lietz G, Miles EA, Cordell H, et al. The impact of common gene variants on the response of biomarkers of cardiovascular disease (CVD) risk to increased fish oil fatty acids intakes. Annu Rev Nutr. 2011;31:203-34.
10. Caslake MJ, Miles EA, Kofler BM, Lietz G, Curtis P, Armah CK, et al. Effect of sex and genotype on cardiovascular biomarker response to fish oils: the FINGEN Study. Am J Clin Nutr. 2008;88:618-29.
11. Masson LF, McNeill G, Avenell A. Genetic variation and the lipid response to dietary intervention: a systematic review. Am J Clin Nutr. 2003;77:1098-111.
12. Minihane AM. Fatty acid-genotype interactions and cardiovascular risk. Prostaglandins Leukot Essent Fatty Acids. 2010;82:259-64.
13. Rudkowska I, Paradis AM, Thifault E, Julien P, Barbier O, Couture P, et al. Differences in meta bolomic and trans criptomic profiles between responders and non-responders to an n-3 polyunsaturated fatty acids (PUFAs) supplementation. Genes Nutr. 2013;8:411-23.
14. Hui DY. Phospholipase A(2) enzymes in metabolic and cardiovascular diseases. Curr Opin Lipidol. 2012;23:235-40.
15. Pratico D. Prostanoid and isoprostanoid pathways in atherogenesis. Atherosclerosis. 2008;201:8-16.
16. Deigner HP, Hermetter A. Oxidized phospholipids: emerging lipid mediators in pathophysiology. Curr Opin Lipidol. 2008;19:289-94.
17. Wymann MP, Schneiter R. Lipid signalling in disease. Nat Rev Mol Cell Biol. 2008;9:162-76.
18. Das UN. Can endogenous lipid molecules serve as predictors and prognostic markers of coronary heart disease? Lipids Health Dis. 2008;7:19.
19. Shimizu T. Lipid mediators in health and disease: enzymes and receptors as therapeutic targets for the regulation of immunity and inflammation. Annu Rev Pharmacol Toxicol. 2009;49:123-50.
20. Cedars A, Jenkins CM, Mancuso DJ, Gross RW. Calcium-independent phospholipases in the heart: mediators of cellular signaling, bioenergetics, and ischemia-induced electro physiologic dysfunction. J Cardiovasc Pharmacol. 2009;53:277-89.
21. Dennis EA, Cao J, Hsu YH, Magrioti V, Kokotos G. Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention. Chem Rev. 2011;111:6130-85.
22. Kugiyama K, Ota Y, Takazoe K, Moriyama Y, Kawano H, Miyao Y, et al. Circulating levels of secretory type II phospholipase A(2) predict coronary events in patients with coronary artery disease. Circulation. 1999;100:1280-4.
23. Mallat Z, Steg PG, Benessiano J, Tanguy ML, Fox KA, Collet JP, et al. Circulating secretory phospholipase A2 activity predicts recurrent events in patients with severe acute coronary syndromes. J Am Coll Cardiol. 2005;46:1249-57.
24. Hartiala J, Li D, Conti DV, Vikman S, Patel Y, Tang WH, et al. Genetic contribution of the leukotriene pathway to coronary artery disease. Hum Genet. 2011;129:617-27.
25. Callaway CW, Chumlea WC, Bouchard C, Himes JH, Lohman TG, Martin AD, et al. Standardization of Anthropomeric Measurements : The Airlie (VA) Consensus Conference. Champaign, IR, USA: Human Kinetics Publishers; 1988. p. 39-80.
26. McNamara JR, Schaefer EJ. Automated enzymatic standardized lipid analyses for plasma and lipoprotein fractions. Clin Chim Acta. 1987;166:1-8.
27. Albers JJ, Warnick GR, Wiebe D, King P, Steiner P, Smith L, et al. Multi-laboratory comparison of three heparin-Mn2+ precipitation procedures for estimating cholesterol in high-density lipoprotein. Clin Chem. 1978;24:853-6.
28. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
29. Laurell CB. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal Bio chem. 1966;15:45-52.
30. Pirro M, Bergeron J, Dagenais GR, Bernard PM, Cantin B, Despres JP, et al. Age and duration of follow-up as modulators of the risk for ischemic heart disease associated with high plasma C-reactive protein levels in men. Arch Intern Med. 2001;161:2474-80.
31. Shaikh NA, Downar E. Time course of changes in porcine myocardial phospholipid levels during ischemia. A reassessment of the lysolipid hypothesis. Circ Res. 1981;49:316-25.
32. Kroger E, Verreault R, Carmichael PH, Lindsay J, Julien P, Dewailly E, et al. Omega-3 fatty acids and risk of dementia: the Canadian study of health and aging. Am J Clin Nutr. 2009;90:184-92.
33. Livak KJ. Allelic discrimination using fluorogenic probes and the 5' nuclease assay. Genet Anal. 1999;14:143-9.
34. Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011;123:2292-333.
35. Cormier H, Rudkowska I, Paradis AM, Thifault E, Garneau V, Lemieux S, et al. Association between polymorphisms in the fatty acid desaturase gene cluster and the plasma triacylglycerol response to an n-3 PUFA supplementation. Nutrients. 2012;4:1026-41.
36. Vittos O, Toana B, Vittos A, Moldoveanu E. Lipoprotein-associated phospholipase A2 (Lp-PLA2): a review of its role and significance as a cardiovascular biomarker. Biomarkers. 2012;17:289-302.
37. Sertic J, Skoric B, Lovric J, Bozina T, Reiner Z. Does Lp-PLA2 determination help predict atherosclerosis and cardio cerebro vascular disease? Acta Med Croatica. 2010;64:237-45.
38. Thifault E, Cormier H, Bouchard-Mercier A, Rudkowska I, Paradis AM, Garneau V, et al. Effects of age, sex, body mass index and APOE genotype on cardiovascular biomarker response to an n-3 polyunsaturated fatty acid supplementation. J Nutrigenet Nutrigenomics. 2013;6:73-82.
39. Tischfield JA, Xia YR, Shih DM, Klisak I, Chen J, Engle SJ, et al. Low-molecular weight, calcium-dependent phospholipase A2 genes are linked and map to homologous chromosome regions in mouse and human. Genomics. 1996;32:328-33.
40. Sato H, Kato R, Isogai Y, Saka G, Ohtsuki M, Taketomi Y, et al. Analyses of group III secreted phospholipase A2 transgenic mice reveal potential participation of this enzyme in plasma lipoprotein modification, macrophage foam cell formation, and atherosclerosis. J Biol Chem. 2008;283:33483-97.
41. Kimura-Matsumoto M, Ishikawa Y, Komiyama K, Tsuruta T, Murakami M, Masuda S, et al. Expression of secretory phospholipase A2s in human atherosclerosis development. Atherosclerosis. 2008;196:81-91.
42. Liu X, Zhu RX, Tian YL, Li Q, Li L, Deng SM, et al. Association of PLA2G7 gene polymorphisms with ischemic stroke in northern Chinese Han population. Clin Bio chem. 2014;47:404-8.
43. Grallert H, Dupuis J, Bis JC, Dehghan A, Barbalic M, Baumert J, et al. Eight genetic loci associated with variation in lipoprotein-associated phospholipase A2 mass and activity and coronary heart disease: meta-analysis of genome-wide association studies from five community-based studies. Eur Heart J. 2012;33:238-51.
44. Sutton BS, Crosslin DR, Shah SH, Nelson SC, Bassil A, Hale AB, et al. Comprehensive genetic analysis of the platelet activating factor acetylhydrolase (PLA2G7) gene and cardiovascular disease in case-control and family datasets. Hum Mol Genet. 2008;17:1318-28.
45. Jang Y, Kim OY, Koh SJ, Chae JS, Ko YG, Kim JY, et al. The Val279Phe variant of the lipoprotein-associated phospholipase A2 gene is associated with catalytic activities and cardiovascular disease in Korean men. J Clin Endocrinol Metab. 2006;91:3521-7.
46. Ninio E, Tregouet D, Carrier JL, Stengel D, Bickel C, Perret C, et al. Platelet-activating factor-acetyl hydro lase and PAF-receptor gene haplotypes in relation to future cardiovascular event in patients with coronary artery disease. Hum Mol Genet. 2004;13:1341-51.
47. Casas JP, Ninio E, Panayiotou A, Palmen J, Cooper JA, Ricketts SL, et al. PLA2G7 genotype, lipoprotein-associated phospholipase A2 activity, and coronary heart disease risk in 10 494 cases and 15 624 controls of European Ancestry. Circulation. 2010;121:2284-93.
48. Hou L, Chen S, Yu H, Lu X, Chen J, Wang L, et al. Associations of PLA2G7 gene polymorphisms with plasma lipoprotein-associated phospholipase A2 activity and coronary heart disease in a Chinese Han population: the Beijing atherosclerosis study. Hum Genet. 2009;125:11-20.
49. Rapoport SI. Translational studies on regulation of brain docosahexaenoic acid (DHA) metabolism in vivo. Prostaglandins Leukot Essent Fatty Acids. 2013;88:79-85.
50. Cheon Y, Kim HW, Igarashi M, Modi HR, Chang L, Ma K, et al. Disturbed brain phospholipid and docosahexaenoic acid metabolism in calcium-independent phospholipase A(2)-VIA (iPLA(2)beta)-knockout mice. Biochim Biophys Acta. 1821;2012:1278-86.
51. Denys A, Hichami A, Khan NA. n-3 PUFAs modulate T-cell activation via protein kinase C-alpha and -epsilon and the NF-kappaB signaling pathway. J Lipid Res. 2005;46:752-8.
52. Han C, Demetris AJ, Michalopoulos G, Shelhamer JH, Wu T. 85-kDa cPLA(2) plays a critical role in PPAR-mediated gene transcription in human hepatoma cells. Am J Physiol Gastrointest Liver Physiol. 2002;282:G586-97.
53. Pawliczak R, Han C, Huang XL, Demetris AJ, Shelhamer JH, Wu T. 85-kDa cytosolic phospholipase A2 mediates peroxisome proliferator-activated receptor gamma activation in human lung epithelial cells. J Biol Chem. 2002;277:33153-63.
54. Calder PC. Mechanisms of action of (n-3) fatty acids. J Nutr. 2012;142:592S-9S.
55. Chaudhuri A, Rosenstock J, DiGenio A, Meneghini L, Hollander P, McGill JB, et al. Comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes: a patient-level pooled analysis. Diabetes Metab Res Rev. 2012;28:258-67.
56. Kong AP, Yamasaki A, Ozaki R, Saito H, Asami T, Ohwada S, et al. A randomized-controlled trial to investigate the effects of rivoglitazone, a novel PPAR gamma agonist on glucose-lipid control in type 2 diabetes. Diabetes Obes Metab. 2011;13:806-13.